




Esperion Therapeutics (Plymouth, MI, USA) has announced the appointment of **Tim Mayleben** (left) as president and CEO, succeeding company founder **Roger Newton** who will become executive chairman and CSO. Mayleben was most recently president and CEO at Aastrom Biosciences. He was previously an advisor to life science companies through his firm EIMa Advisors and COO and CFO of the original Esperion Therapeutics, where he raised more than \$200 million in venture and equity capital and negotiated the sale of the company to Pfizer for \$1.3 billion in 2004.

"Under Roger's leadership, the development of Esperion's lead compound ETC-1002 has advanced rapidly and shown tremendous clinical and therapeutic potential. I am excited to be working with Roger again and look forward to helping the Esperion team realize the full potential of ETC-1002 and our broader portfolio of lipid-regulating therapies to treat cardiometabolic diseases. I share their passion and commitment to this important therapeutic area and believe the next few years will be a very exciting and rewarding time for Esperion," Mr. Mayleben said.

management team. Mount, who was previously at Pfizer, joins as chief clinical officer; Ward, previously at Stabilitech and Onyvax, joins as COO; and chief business officer Durdy joins from Aqix, where he was CEO.

DEINOVE (Paris) has announced the appointment of **Emmanuel Petiot**, formerly director of sales at Novozymes North America, as CEO. He replaces **Jacques Biton**, who had served as CEO since 2007 and will become chairman of the company's scientific advisory board.

**John C. Reed** (right) has been appointed head of the pharma Research and Early Development (pRED) group at Roche (Basel) effective on April 2, 2013, replacing interim head **Mike Burgess**, who has decided to leave Roche. Reed has been CEO at Sanford-Burnham Medical Research Institute and the founder, co-founder or director of a number of biotech companies.



La Jolla Pharmaceutical Company (San Diego) has announced the additions of **Stacey Ruiz** and **Chester S. Zygmunt** to its management team. Ruiz, the company's new director of R&D, was previously at Reata Pharmaceuticals. Zygmunt brings 10 years of finance experience to La Jolla, having previously served as managing director of Z3 Capital.

**Lesley Russell** has joined the board of directors of Endocyte (W. Lafayette, IN, USA). She previously served as senior vice president and head of R&D for global branded products at Teva Pharmaceuticals until June 2012. Before that, she was executive vice president and chief medical officer at Cephalon.

Aratana Therapeutics (Kansas City, KS, USA) has appointed **Julia A. Stephanus** as chief commercial officer. Stephanus has more than 25 years of animal health marketing experience, most recently serving as director of the companion animal global franchise for Ceva Animal Health. She also founded Summit VetPharm in 2005.

**Gerhard F. Burbach** has been appointed to the board of directors of Fluidigm (S. San Francisco, CA, USA). He will also join the board's audit and compensation committees. He currently serves as president, CEO and director of publicly traded Thoratec.

Orgenesis (White Plains, NY, USA) has announced the appointment of **Sav DiPasquale** as president and CEO. He succeeds **Jacob BenArie**, who has been appointed CEO of the company's private subsidiary, Orgenesis Ltd. Prior to joining Orgenesis, DiPasquale worked with GlaxoSmithKline in Canada, most recently serving as vice president, business development and corporate planning.

Seegene (Seoul) has named **John G. Hurrell** as senior executive vice president in charge of the company's B2B business unit based in Gaithersburg, Maryland. Most recently Hurrell served as president and general manager of Focus Diagnostics, a subsidiary of Quest Diagnostics.

**Bahija Jallal** has been appointed president of MedImmune (Gaithersburg, MD, USA), succeeding **Peter Greenleaf**, who is leaving to head parent company AstraZeneca's Latin America business. Jallal, who previously served as MedImmune's executive vice president of R&D, joined the company in 2006 as vice president of translational sciences.

SciClone Pharmaceuticals (Foster City, CA, USA) has appointed **Simon Li** to its board of directors. Li brings more than 30 years of management experience in multinational companies. He most recently served as the global officer and member of the executive committee of Medtronic, and also held the positions of president, Greater China, and chairman of the board of Medtronic-Weigao JV.

Start-up vaccine developer Hookipa Biotech (Vienna) has named **Thomas P. Monath** as chief medical officer and **Farshad Guirakhoo** as CSO. Monath is a former partner in the Pandemic and Biodefense Fund, Kleiner Perkins Caufield & Byers and adjunct professor at the Harvard School of Public Health. Between 1992 and 2006, he served as CSO and executive director of Acambis. Guirakhoo comes to Hookipa from Sanofi Pasteur, where he held the position of senior director of external R&D.

Tranzyme Pharma (Research Triangle Park, NC, USA) has named **David S. Moore** as chief business officer. Moore joined Tranzyme in August 2011 from Johnson & Johnson as vice president, commercial operations, and his responsibilities were increased in January 2012 to include the oversight of business development.

The Cell Therapy Catapult (London), a center of translational excellence for regenerative medicine, has named **Natalie Mount**, **Stephen Ward** and **Matthew Durdy** to its